参考文献：
1. Williams K, Lada G, Reynolds NJ, et al. Risk of Suicide and Suicidality in Patients with Moderate to Severe Psoriasis: results from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Clin Exp Dermatol. Published online October 19, 2024. doi:10.1093/ced/llae449
2. Zhang J, Ding Y, Wang P, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. Br J Dermatol. Published online October 22, 2024. doi:10.1093/bjd/ljae406
3. Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks. Br J Dermatol. Published online October 23, 2024. doi:10.1093/bjd/ljae402
